About: Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study
Creator	Balkhy, Hanan Fowler, Robert Alraddadi, Basem Al-Omari, Awad Al-Dawood, Abdulaziz Al-Hameed, Fahad Almotairi, Abdullah Jose, Jesna Kharaba, Ayman Mandourah, Yasser Qushmaq, Ismael Shalhoub, Sarah Hayden, Frederick Merson, Laura Arabi, Yaseen Al Harthy, Abdulrahman Mady, Ahmed Abdulmomen, Ahmed Al Khatib, Kasim Al Qasim, Eman Al-Raddadi, Rajaa Ragab, Ahmed Solaiman, Othman Sindi, Anees Al Mekhlafi, Ghaleb Al-Aithan, Abdulsalam Arabi, Y Maghrabi, Khalid Gramish, Jawaher
Source	Medline; PMC
abstract	BACKGROUND: The objective of this study was to evaluate the effect of ribavirin and recombinant interferon (RBV/rIFN) therapy on the outcomes of critically ill patients with Middle East respiratory syndrome (MERS), accounting for time-varying confounders. METHODS: This is a retrospective cohort study of critically ill patients with laboratory-confirmed MERS from 14 hospitals in Saudi Arabia diagnosed between September 2012 and January 2018. We evaluated the association of RBV/rIFN with 90-day mortality and MERS coronavirus (MERS-CoV) RNA clearance using marginal structural modeling to account for baseline and time-varying confounders. RESULTS: Of 349 MERS patients, 144 (41.3%) patients received RBV/rIFN (RBV and/or rIFN-α2a, rIFN-α2b, or rIFN-β1a; none received rIFN-β1b). RBV/rIFN was initiated at a median of 2 days (Q1, Q3: 1, 3 days) from intensive care unit admission. Crude 90-day mortality was higher in patients with RBV/rIFN compared to no RBV/rIFN (106/144 [73.6%] vs 126/205 [61.5%]; P = .02]. After adjusting for baseline and time-varying confounders using a marginal structural model, RBV/rIFN was not associated with changes in 90-day mortality (adjusted odds ratio, 1.03 [95% confidence interval {CI}, .73–1.44]; P = .87) or with more rapid MERS-CoV RNA clearance (adjusted hazard ratio, 0.65 [95% CI, .30–1.44]; P = .29). CONCLUSIONS: In this observational study, RBV/rIFN (RBV and/or rIFN-α2a, rIFN-α2b, or rIFN-β1a) therapy was commonly used in critically ill MERS patients but was not associated with reduction in 90-day mortality or in faster MERS-CoV RNA clearance.
has issue date	2019-06-25(xsd:dateTime)
bibo:doi	10.1093/cid/ciz544
bibo:pmid	31925415
has license	no-cc
sha1sum (hex)	7217d2270fe8b796b95545af6cbe6001cf6f1836
schema:url	https://doi.org/10.1093/cid/ciz544
resource representing a document's title	Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study
has PubMed Central identifier	PMC7108209
has PubMed identifier	31925415
schema:publication	Clin Infect Dis
resource representing a document's body	covid:7217d2270fe8b796b95545af6cbe6001cf6f1836#body_text
is schema:about of	named entity 'Middle East respiratory syndrome' named entity 'Ribavirin' named entity 'PATIENTS' named entity 'Critically' named entity 'confounders' named entity 'Middle East respiratory syndrome' named entity 'MERS' named entity 'Middle East Respiratory Syndrome' named entity 'Critically Ill Patients' named entity 'corticosteroids' named entity 'confounders' named entity 'MERS-CoV' named entity 'renal disease' named entity 'rhesus macaques' named entity 'intensive care units' named entity 'WBC' named entity 'RNA' named entity 'hemoglobin' named entity 'safety profile' named entity 'comorbidities' named entity 'preclinical studies' named entity 'white blood cell (WBC) count' named entity 'Infection' named entity 'observational studies' named entity 'SAS' named entity 'confounders' named entity 'AST' named entity 'AST' named entity 'RNA' named entity 'severe acute respiratory syndrome' named entity 'nasopharyngeal swabs' named entity 'open reading frame' named entity 'therapeutic interventions' named entity 'Cox proportional hazards model' named entity 'MERS' named entity 'critically ill patients' named entity 'renal replacement therapy' named entity 'clinical presentation' named entity 'MERS-CoV' named entity 'preclinical' named entity 'AST' named entity 'Rockland, Massachusetts' named entity 'average weight' named entity 'guanosine' named entity 'pneumonia' named entity 'Whitehouse Station' named entity 'confounding' named entity 'aspartate aminotransferase' named entity 'oxygen' named entity 'confounders' named entity 'aspartate aminotransferase' named entity 'MERS' named entity 'RNA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software